FDA approves first drug to treat COVID-19

October 22, local time, the FDA approved the first drug for the treatment of COVID-19 patients, which is the biotechnology giant Gilead developed the Redsivir (product named Veklury), which is currently the only antiviral drug approved by the FDA for the treatment of COVID-19 patients.Gilead said Redsiwe was approved or licensed to use as a temporary treatment for Covid-19 in about 50 countries around the world.Most patients treated with Redsyvir received a five-day course of treatment using six vials of the drug. The company is also developing an inhalation drug that is given through an atomizer. In response, Gilead said the drug could not be given as a pill because its chemical composition affects the liver.In May, the FDA approved emergency approval for the drug, which can be used by hospitals and doctors for patients hospitalized with COVID-19, even if it has not yet been formally approved by the FDA. Intravenous administration has helped shorten the recovery time of some hospitalized Covid-19 patients, one of the drugs used to treat U.S. President Donald Trump.Gilead said in August that it planned to produce more than 2m treatments by the end of the year and was on track to achieve "millions of times more growth" by 2021. The supply of the drug has increased more than 50-times since January, and its manufacturing network now includes more than 40 companies in North America, Europe and Asia.Under the Federal Food, Drug and Cosmetic Act, the approval of new drugs requires valid evidence and proof of safety for the intended use of the drug. When considering approving a drug, the FDA conducts an interest risk assessment based on strict scientific criteria to ensure that the product's benefits outweigh its risks to the intended population. The agency's analysis of data from three randomized, controlled clinical trials, including mild to severe COVID-19 patients in hospital, supported Veklury's approval."The FDA is committed to accelerating the development and availability of COVID-19 treatment in this unprecedented public health emergency," said FDA Commissioner Dr. Stephen M. Hahn, "today's approval is supported by several clinical trial data rigorously evaluated by the FDA and represents an important scientific milestone in the COVID-19 pandemic." As part of the FDA Coronavirus Treatment Acceleration Program, we will continue to help transfer new medical products to patients as soon as possible, while determining whether they are effective and whether their benefits outweigh the risks. (Biological Exploration):.[2].